Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jun;40(3):874-883.
doi: 10.1007/s12640-022-00513-7. Epub 2022 Apr 27.

Targeting Insulin-Like Growth Factor-I in Management of Neurological Disorders

Rashita Makkar  1 , Tapan Behl  2 , Aayush Sehgal  1 , Sukhbir Singh  1 , Neelam Sharma  1 , Hafiz A Makeen  3 , Mohammed Albratty  4 , Hassan A Alhazmi  4   5 , Aldulkarim M Meraya  6
Affiliations
Review

Targeting Insulin-Like Growth Factor-I in Management of Neurological Disorders

Rashita Makkar et al. Neurotox Res. 2022 Jun.

Abstract

The degradation of neurons marks as the pathological reason for onset of most of the neurological diseases although the functional deficiencies and symptoms may vary. Insulin-like growth factor-I (IGF-I) boosts regeneration of both motor and sensory neurons and thus presents as a potential treatment in management of neurological disorders. IGF-I is a pleiotropic agent which stimulates the survival and outgrowth of neurons accompanied by their motility as well as myelination by glial cells. This hormone has been found to possess neuroprotective properties which is in association with its antioxidant and mitochondrial protection activity. Studying and exploring the signaling pathways which mediate pleotropic responses intracellularly have elucidated significant therapeutic approach in treatment and management of neurological disorders by IGF-I. The current review highlights the role of IGF-I in management of major neurological disorders such as depression, Parkinson's disease, and Alzheimer's disease and also covers the mechanisms involved in the process.

Keywords: Alzheimer’s disease; Depression; Insulin-like growth factor; Neurodegeneration; Parkinson’s disease.

PubMed Disclaimer

References

    1. Aguirre GA, De Ita JR, de la Garza RG, Castilla-Cortazar I (2016) Insulin-like growth factor-1 deficiency and metabolic syndrome. J Transl Med 14(1):3 - PubMed - PMC - DOI
    1. Alberini CM, Chen DY (2012) Memory enhancement: consolidation, reconsolidation and insulin-like growth factor 2. Trends Neurosci 35:274–283 - PubMed - PMC - DOI
    1. American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders. 5th ed. Arlington: American Psychiatric Association.
    1. Anderson LJ, Tamayose JM, Garcia JM (2018) Use of growth hormone, IGF-I, and insulin for anabolic purpose: pharmacological basis, methods of detection, and adverse effects. Mol Cell Endocrinol 464:65–74 - PubMed - DOI
    1. Annunziata M, Granata R, Ghigo E (2011) The IGF system. Acta Diabetol 48(1):1–9

MeSH terms

Substances

LinkOut - more resources